Optimizing Frontline Therapy for DLBCL in Older Adults: A GLOfitamab-based, Response-adapted, Window-stYle Study (GLORY)

Summary

The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).

Eligibility

Age range

65–80 years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Glofitamab

  C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks

• Drug
  Polatuzumab

  1.8 mg/kg iv C1D1 onwards, every 3 weeks

• Drug
  Rituximab

  375 mg/m2 iv D1

• Drug
  Cyclophosphamide

  400 mg/m2 iv D1

• Drug
  Doxorubicin

  25 mg/m2 iv D1

• Drug
  Obinutuzumab:

  1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose

Locations (7)